References
- World Health Organization. Geneva: World Health Organization . 2023. Epilepsy fact sheet.
- Mohammadzadeh P, Nazarbaghi S. The prevalence of drug-resistant-epilepsy and its associated factors in patients with epilepsy. Clin Neurol Neurosurg . 2022;213:107086.
- Avanzini G, Franceschetti S. Mechanisms of Epileptogenesis. In: Simon Shorvon, Emilio Perucca, Jerome Engel, editors. The Treatment of Epilepsy. Fourth Edition. John Wiley & Sons; 2016. p. 38–51.
- Savjani KT, Gajjar AK, Savjani JK. Drug Solubility: Importance and Enhancement Techniques. ISRN Pharm. 2012 Jul 5;2012:1–10.
- Johannessen Landmark C, Johannessen SI, Tomson T. Host factors affecting antiepileptic drug delivery—Pharmacokinetic variability. Adv Drug Deliv Rev . 2012;64(10):896–910.
- Fattorusso A, Matricardi S, Mencaroni E, Dell’Isola GB, Di Cara G, Striano P, et al. The Pharmacoresistant Epilepsy: An Overview on Existant and New Emerging Therapies. Vol. 12, Frontiers in Neurology. Frontiers Media S.A.; 2021.
- Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Vol. 12, Nature Reviews Drug Discovery. 2013. p. 757–76.
- Simonato M, Brooks-Kayal AR, Engel J, Galanopoulou AS, Jensen FE, Moshé SL, et al. The challenge and promise of anti-epileptic therapy development in animal models. Lancet Neurol. 2014 Sep;13(9):949—960.
- Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: Ways out of the current dilemma. Vol. 52, Epilepsia. 2011. p. 657–78.
- Campos G, Fortuna A, Falcão A, Alves G. In vitro and in vivo experimental models employed in the discovery and development of antiepileptic drugs for pharmacoresistant epilepsy. Epilepsy Res . 2018;146:63–86.
- Burnham WM. Why are Complex Partial Seizures Intractable? In: Burnham W. McIntyre and Carlen PL and HPA, editor. Intractable Seizures: Diagnosis, Treatment, and Prevention. Boston, MA: Springer US; 2002. p. 107–10.
- Reddy DS, Kuruba R. Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions. Vol. 14, International Journal of Molecular Sciences. 2013. p. 18284–318.
- Albus K, Wahab A, Heinemann U. Standard antiepileptic drugs fail to block epileptiform activity in rat organotypic hippocampal slice cultures. Br J Pharmacol. 2008 Jun 14;154(3):709–24.
- Anderson WW, Lewis D V, Swartzwelder HS, Wilson WA. Magnesium-free medium activates seizure-like events in the rat hippocampal slice. Brain Res. 1986;398:215–9.
- Heinemann U, Kann O, Schuchmann S. An Overview of In Vitro Seizure Models in Acute and Organotypic Slices. In: Models of Seizures and Epilepsy. 2006: 35–44.
- Bazhenov M, Timofeev I, Steriade M, Sejnowski TJ. Potassium Model for Slow (2-3 Hz) In Vivo Neocortical Paroxysmal Oscillations. J Neurophysiol. 2004;92(2):1116–32.
- Mody I, Lambert JDC, Heinemann U. Low Extracellular Magnesium Induces Epileptiform Activity and Spreading Depression in Rat Hippocampal Slices . Vol. 57, JOURNAL OF NEUROPHYSIOL~GY. 1987. Available from: www.physiology.org/journal/jn
- Johannessen SI, Gerna M, Bakke J, Strandjord RE, Morselli PL. CSF Concentrations and Serum Protein Binding of Carbamazepoine and Carbamazepine-10, 11-Epoxide in Epileptic Patients. Br J Clin Pharmacol. 1976;3(4):575–82.
- National Center for Biotechnology Information. 2024 [cited 2024 Jan 15]. PubChem Compound Summary for CID 2554, Carbamazepine. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Carbamazepine.
- Bonifácio MJ, Sheridan RD, Parada A, Cunha RA, Patmore L, Soares-Da-Silva P. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: Comparison with carbamazepine. Epilepsia. 2001;42(5):600–8.
- Barzegar-Jalali M, Nayebi AM, Valizadeh H, Hanaee J, Barzegar-Jalali A, Adibkia K, et al. Evaluation of in vitro-in vivo correlation and anticonvulsive effect of carbamazepine after cogrinding with microcrystalline cellulose. Vol. 9, J Pharm Pharmaceut Sci (www.cspsCanada.org). 2006.
- Kumar R, Siril PF. Ultrafine carbamazepine nanoparticles with enhanced water solubility and rate of dissolution. RSC Adv. 2014;4(89):48101–8.
- Qushawy M, Prabahar K, Abd-Alhaseeb M, Swidan S, Nasr A. Preparation and evaluation of carbamazepine solid lipid nanoparticle for alleviating seizure activity in pentylenetetrazole-kindled mice. Molecules. 2019;24(21):3971.
- Scioli Montoto S, Sbaraglini ML, Talevi A, Couyoupetrou M, Di Ianni M, Pesce GO, et al. Carbamazepine-loaded solid lipid nanoparticles and nanostructured lipid carriers: Physicochemical characterization and in vitro/in vivo evaluation. Colloids Surf B Biointerfaces. 2018 Jul 1;167:73–81.
- Frijlink HW, Visser J, Hefting NR, Oosting R, Meijer DKF, Lerk CF. The Pharmacokinetics of P-Cyclodextrin and Hydroxypropyl-JJ-cyclodextrin in the Rat. Vol. 7, Pharmaceutical Research. 1990.
- Hirayama F, Uekama K. Cyclodextrin-based controlled drug release system. Adv Drug Deliv Rev. 1999;36(1):125–41.
- Koester LS, Bertuol JB, Groch KR, Xavier CR, Moellerke R, Mayorga P, et al. Bioavailability of carbamazepine:β-cyclodextrin complex in beagle dogs from hydroxypropylmethylcellulose matrix tablets. Eur J Pharm Sci. 2004;22(2):201–7.
- Veszelka S, Mészáros M, Porkoláb G, Rusznyák Á, Réti-Nagy KS, Deli MA, et al. Effects of Hydroxypropyl-Beta-Cyclodextrin on Cultured Brain Endothelial Cells. Molecules. 2022 Nov 1;27(22):7738.
- Pytel M, Mercik K, Mozrzymas JW. Interaction between cyclodextrin and neuronal membrane results in modulation of GABA A receptor conformational transitions. Br J Pharmacol. 2006 Jun 8;148(4):413–22.
- Zhang ZJ, Koifman J, Shin DS, Ye H, Florez CM, Zhang L, et al. Transition to seizure: Ictal discharge is preceded by exhausted presynaptic GABA release in the hippocampal CA3 region. Journal of Neuroscience. 2012;32(7): 2499–2512.
- Wahab A, Albus K, Gabriel S, Heinemann U. In search of models of pharmacoresistant epilepsy. Epilepsia. 2010;51(s3):154–9.
- Quilichini PP, Diabira D, Chiron C, Milh M, Ben-Ari Y, Gozlan H. Effects of Antiepileptic Drugs on Refractory Seizures in the Intact Immature Corticohippocampal Formation In Vitro. Epilepsia. 2003;44(11):1365–74.
- D’Antuono M, Köhling R, Ricalzone S, Gotman J, Biagini G, Avoli M. Antiepileptic drugs abolish ictal but not interictal epileptiform discharges in vitro. Epilepsia. 2010;51(3):423–31.
- Gáll Z, Orbán-Kis K, Szilágyi T. Differential effects of sodium channel blockers on in vitro induced epileptiform activities. Arch Pharm Res. 2017 Jan 1;40(1):112–21.
- Rouaz K, Chiclana-Rodríguez B, Nardi-Ricart A, Suñé-Pou M, Mercadé-Frutos D, Suñé-Negre JM, et al. Excipients in the Paediatric Population: A Review. Pharmaceutics. 2021;13(3):387.
- Ahmed A. Does polyethylene glycol, used as an excipient at mRNA-based (Moderna, Pfizer) vaccines, cause an increase in the frequency of epilepsy in PWE? 2022.